Pipeline
BRY101
An oral NAD+ medical food in Phase 1b dose finding for wound healing. Preclinical data shows penetration into spinal cord tissue.
- Preclinical
- Phase 1b dose finding
Built on a proven platform
BRY101 uses the formulation evaluated in RENEWAL-NAD+, where intracellular NAD rose 53% versus placebo over five days with a favorable short-term safety profile.
53%
increase in intracellular NAD versus placebo in RENEWAL-NAD+, over five days.
25.7%
increase in spinal cord NAD+ within four hours, in an ALS mouse model.
Reaches central nervous system tissue
In a 48-hour study in an ALS mouse model conducted with the ALS Therapy Development Institute, oral administration produced a 25.7% increase in spinal cord NAD+ within four hours.
Federal research pathway
Bryleos has executed a Master CRADA with the U.S. Military to enable a proof-of-concept wound healing study and explore further federal research collaboration.
What is next
A second publication reporting multi-omic analyses from RENEWAL-NAD+